XML 56 R49.htm IDEA: XBRL DOCUMENT v3.24.3
Convertible Loan Notes (Additional Information) (Details)
£ / shares in Units, £ in Millions, $ in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 10, 2023
USD ($)
shares
Feb. 10, 2020
GBP (£)
£ / shares
shares
May 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
shares
Jun. 30, 2023
shares
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
£ / shares
Dec. 31, 2020
£ / shares
Feb. 10, 2020
USD ($)
shares
Ordinary Shares | Novartis Pharma [Member]                          
Debt Instrument [Line Items]                          
Exercise Price of Warrants Issued | £ / shares   £ 0.265                      
Novartis Loan Note [Member]                          
Debt Instrument [Line Items]                          
Debt Instrument, Interest Rate   6.00%                     6.00%
Carrying Value of Debt Instrument       $ 5.6     $ 5.6     $ 4.4      
Fair value of convertible debt       $ 5.1     $ 5.1            
Debt Instrument, Effective Interest Rate       27.80% 27.80%   27.80% 27.80%          
Novartis Loan Note [Member] | After Amendments [Member]                          
Debt Instrument [Line Items]                          
Debt Instrument, Effective Interest Rate         37.40%     37.40%          
Novartis Loan Note [Member] | Novartis Pharma [Member]                          
Debt Instrument [Line Items]                          
Amount of Convertible Note   £ 3.8                     $ 5.2
Conversion Price Per Share | £ / shares   £ 0.265                      
Debt Instrument, Maturity Date   Feb. 10, 2023                      
Warrants Convertible in Equity | shares   1,449,614                     1,449,614
Debt Instrument, Extended Maturity Date Feb. 10, 2025                        
Debt Instrument, Amended Interest Rate 9.00%                        
Debt Instrument, Amended Accrued Interest $ 0.9                        
Novartis Loan Note [Member] | Ordinary Shares | Novartis Pharma [Member]                          
Debt Instrument [Line Items]                          
Warrants Convertible in Equity | shares 2,000,000                        
New Novartis Loan Note [Member]                          
Debt Instrument [Line Items]                          
Carrying Value of Debt Instrument $ 5.5                        
Debt Instrument, Consideration, Liability Recognised Two 3.4                        
Debt Instrument, Interest Paid in Cash 0.9                        
Relative Fair value of the Warrants and The Conversion Option 1.2                        
Gain (Loss) on Extinguishment of Debt $ 0.0                        
Debt, Interest Expense       $ 0.3 $ 0.3   $ 0.9 $ 0.8          
Convertible Debt Instrument [Member] | Private Placement Loan Notes                          
Debt Instrument [Line Items]                          
Debt Instrument, Interest Rate                       6.00%  
Debt Instrument, Maturity Date                 Jun. 03, 2023        
Debt Instrument, Extended Maturity Date     Aug. 03, 2023                    
Debt, Interest Expense         0.4     1.5          
Debt Instrument, Effective Interest Rate       27.10%     27.10%     25.10%      
Debt Instrument, Aggregate Principal Amount         $ 4.6     $ 4.6          
Issuance of Private Placement Loan Notes                 $ 70.0        
Changes in Carrying Value of Debt Instrument     $ 0.6                    
Payment of Debt Outstanding Amount                   $ 3.2      
Convertible Debt Instrument [Member] | Ordinary Shares | Private Placement Loan Notes                          
Debt Instrument [Line Items]                          
Conversion Price Per Share | £ / shares                       £ 0.174  
Conversion of notes into ordinary shares | shares         9,645,200 17,774,895              
Share Issued, Price per Share | £ / shares                     £ 0.174